Financings in Brief: Nanogen
This article was originally published in The Gray Sheet
Nanogen: Completes $2.5 mil. round of venture capital financing, bringing the total raised this year to $9 mil. and the total raised since inception to $13 mil. The San Diego-based development-stage firm says its initial focus is on "rapid panel test opportunities in human DNA probe diagnostics." InterWest Partners of Menlo Park, California was a major investor in the current round, which is expected to fund R&D for the next 12-18 months. Separately, Nanogen says it "recently received a $2 mil., two-year grant from the U.S. Department of Commerce to fund development of an integrated microelectronic DNA diagnostic system"...
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.